Method for screening for candidate substances for treating cranial nerve development disease or cranial nerve toxic substances by using cerebral organoid

Cerebral organoids derived from human induced pluripotent stem cells are used to screen neurotoxic substances and therapeutic candidates, addressing the need for effective models to evaluate the impact of fine dust and air pollutants on brain tissue, thereby facilitating the identification of neurotoxic effects and potential treatments.

WO2024232650A1PCT designated stage expired Publication Date: 2024-11-14SOGANG UNIV RES & BUSINESS DEV FOUND

Patent Information

Application Number
PCT/KR2024/006164
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods lack effective models for screening neurotoxic substances and therapeutic candidates for neurodevelopmental diseases, particularly in mimicking the effects of fine dust and air pollutants on brain tissue, which are crucial for understanding their impact and developing treatments.

Method used

The development of a method using cerebral organoids derived from human induced pluripotent stem cells, which involves spheroid formation, differentiation, contact with test substances, and analysis of structural or functional damage, allowing for the evaluation of neurotoxic effects and potential treatments through electrophysiological and immunological staining techniques.

Benefits of technology

This method enables the assessment of neurotoxicity and therapeutic efficacy by observing changes in cerebral organoids exposed to nano-sized diesel exhaust particles, providing insights into brain tissue damage and potential treatments for neurodevelopmental diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006164_14112024_PF_FP_ABST
    Figure KR2024006164_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a method for screening for candidate substances for treating cranial nerve development disease or cranial nerve toxic substances by using a cerebral organoid. This screening system is utilized to evaluate the effects, on brain neural tissue and synaptic plasticity, of air pollutants, and nanomaterials contained in everyday food formulations, particularly, nanocalcium, for improving absorption and functions, as well as in food additives, preservatives, packaging materials and the like for facilitating storage and distribution.
Need to check novelty before this filing date? Find Prior Art

Description

Method for screening for neurotoxic substances or candidate substances for the treatment of neurodevelopmental diseases using cerebral organoids

[0001] The present invention was made with the support of the Ministry of Science and ICT under the task identification number 1711187608 and the detailed task number 2022M3H4A1A01005271. The research management specialized organization of the task is the National Research Foundation of Korea, the research project name is "Nanomaterial Technology Development", the research project name is "Nano-biohybrid actuator chip for organoid-based drug screening", the main organization is Sogang University, and the research period is 2022-01-01 ~ 2022-12-31.

[0002] In addition, the present invention was made under the support of the Ministry of Education under the task identification number 1345354116 and the detailed task number 2022R1I1A1A01069710, and the research management specialized institution of the said task is the National Research Foundation of Korea, the research project name is "Creative Challenge Research Base Support", the research task name is "Development of an in vitro disease model of the thalamus-midbrain assembler derived from Parkinson's disease patient cells capable of monitoring the effects of ultrafine dust and screening for therapeutic drugs", the main institution is Sogang University, and the research period is 2022-06-01 ~ 2023-02-28.

[0003] In addition, the present invention was made with the support of the Ministry of Science and ICT under the task identification number 1711198532 and the detailed task number RS-2023-00259341. The research management specialized organization of the said task is the National Research Foundation of Korea, the research project name is "Establishment of an Overseas Excellent Research Institution Cooperation Hub", the research project name is "Sogang-UPenn Emerging Infectious Disease Theranostics Convergence Research Center", the main organization is Sogang University, and the research period is 2023-07-01 ~ 2028-12-31.

[0004] This patent application claims priority to Republic of Korea Patent Application No. 10-2023-0059788, filed with the Korean Intellectual Property Office on May 9, 2023, the disclosure of which is incorporated herein by reference.

[0005] The present invention relates to a method for screening a neurotoxic substance or a candidate substance for treating a neurodevelopmental disease using a cerebral organoid, and more specifically, to providing a cerebral organoid that can be used as a model for screening because the growth is affected when a toxic substance is treated during the process of inducing growth and differentiation of a cerebral organoid tissue, and can also be used as an evaluation index for a neurodevelopmental disease of the neurodevelopmental system of the brain.

[0006] Organoids, also known as 'organoids', are made by re-aggregating and recombining cells isolated from stem cells or organs through three-dimensional culture, and can be used as models for various studies on development and disease because they can recreate the organization and functions of living organs similar to actual organs.

[0007] In 2013, British researchers created brain organoids with functional and structural similarities to the cerebrum. These organoids were organized into tissue-like structures with characteristics similar to the general brain, without differentiation into specific regions. Since then, numerous researchers have produced and published brain organoids from various regions.

[0008] Meanwhile, particulate matter (PM) is a term that refers to a mixture of small solid particles and liquid droplets floating in the air, and today, particulate matter is receiving a lot of attention due to its health hazards.

[0009] Dust is divided into total suspended particles (TSP), which are particles with a diameter of 50 μm or less, and fine dust (PM). Fine dust is further divided into PM 10, which is 10 μm or less in diameter, PM 2.5, which is 2.5 μm or less in diameter, and PM 0.1, which is 0.1 μm (100 nm) or less in diameter.

[0010] Automobile exhaust fumes, a major cause of air pollution, particularly diesel exhaust particulate matter (DPM), have an aerodynamic diameter of less than 2.5 μm, with most being PM 0.1 particles with a diameter of less than 100 nm. These particles remain in the atmosphere for long periods of time and affect the human body through various routes. Most DPM are small enough to be inhaled into the lungs, and while most inhaled particles are subsequently exhaled, some settle on the lung surfaces.

[0011] Nano-sized DPM, some of which is PM 0.1, also has the same non-cancerous effects as exposure to nanoparticles. These effects include asthma, increased respiratory symptoms, and premature death from worsening chronic heart and lung diseases, including decreased lung function in children. Children, whose lungs are still developing, and the elderly, who often suffer from chronic health problems, are most vulnerable to the effects of DPM.

[0012] Nanoparticles can reach the brain via two routes: the indirect route, which involves traveling through the bloodstream and crossing the blood-brain barrier (BBB), and the direct route, which involves traveling through the nasal cavity and the olfactory nerve. The olfactory nerve pathway is the route where direct effects of nanoparticles can be observed.

[0013] The multielectrode array system (MEA) is a device that uses multiple electrodes to simultaneously measure the action potentials of neurons. By measuring changes in the action potentials of brain organoids, it can be used for analysis of electrophysiological changes, changes in ion channels of neurons, signal transmission speed, and detection of signal transmission between neurons.

[0014] Accordingly, the inventors of the present invention attempted to confirm the effects of nanoparticles on the brain through a direct route in brain organoids. After producing cerebral organoids and treating them with nano-sized diesel exhaust particles at various concentrations, they were able to confirm damage to tissues and cells caused by nanoparticles through electrophysiological methods and histoimmunological staining methods.

[0015] Accordingly, an object of the present invention is to provide a method for screening neurotoxic substances comprising the following steps:

[0016] Spheroid formation step in which stem cells are suspended and cultured to form spheroids;

[0017] A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A and differentiated into cerebral organoids;

[0018] A contact step in which a test substance is brought into contact with the neuroepithelial bud formed in the above cerebral organoid;

[0019] A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and

[0020] An analysis step for comparing the degree of occurrence of structural or functional damage in the above cerebral organoids with that of a control group that was not exposed to the test substance.

[0021] Another object of the present invention is to provide a method for screening a candidate substance for treating a brain and nerve developmental disease, comprising the following steps:

[0022] Spheroid formation step of forming spheroids by suspending and culturing stem cells;

[0023] A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A and differentiated into cerebral organoids;

[0024] A contact step in which a toxic substance or therapeutic candidate is brought into contact with the neuroepithelial bud formed in the above cerebral organoid;

[0025] A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and

[0026] An analysis step that compares the degree of improvement in structural or functional damage according to the presence or absence of contact with a therapeutic candidate substance or the amount of treatment among brain organoids exposed to a toxic substance.

[0027] Another object of the present invention relates to the use of cerebral organoids for screening neurotoxic substances or candidate substances for treating neurodevelopmental diseases.

[0028] The present invention relates to a method for screening a candidate substance for treating a neurotoxic substance or a neurodevelopmental disease using a cerebral organoid. The cerebral organoid according to the present invention is cultured for 3 months or more after differentiation is induced from human induced pluripotent stem cells (hiPSCs). The organoid can observe changes in electrical signals due to exposure to nano-sized diesel exhaust particulate matters (DPM) through a multi-channel electrode array system (MEA), and can confirm changes in neurotransmitter secretion and cell tissue through fluorescent staining. Therefore, the organoid can be used to measure damage to brain neural tissue and changes in synaptic plasticity caused by air pollutants such as nanoparticles, microplastics, and micrometals.

[0029] Hereinafter, the present invention will be described in more detail.

[0030] One aspect of the present invention is a method for screening for neurotoxic substances, comprising the following steps:

[0031] Spheroid formation step in which stem cells are suspended and cultured to form spheroids;

[0032] A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A and differentiated into cerebral organoids;

[0033] A contact step in which a test substance is brought into contact with the neuroepithelial bud formed in the above cerebral organoid;

[0034] A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and

[0035] An analysis step for comparing the degree of occurrence of structural or functional damage in the above cerebral organoids with that of a control group that was not exposed to the test substance.

[0036] In the present invention, the stem cell may be at least one selected from the group consisting of human induced pluripotent stem cells (hiPSCs), human embryonic stem cells (hESCs), and human pluripotent stem cells (hPSCs), and may be, for example, hiPSCs, but is not limited thereto.

[0037] In the present invention, the spheroid formation step may be performed by distributing stem cells separated into single cells and suspended in culture to form spheroids at 10,000 to 1,000,000 cells / well, preferably 10,000 to 500,000 cells / well, 10,000 to 200,000 cells / well, 10,000 to 100,000 cells / well, 20,000 to 1,000,000 cells / well, 20,000 to 500,000 cells / well, 20,000 to 200,000 cells / well, 20,000 to 100,000 cells / well, 50,000 to 1,000,000 cells / well, 50,000 to 500,000 It may be performed by dispensing cells / well, 50,000 to 200,000 cells / well, 50,000 to 100,000 cells / well, 100,000 to 1,000,000 cells / well, or 100,000 to 500,000 cells / well, and for example, it may be performed by dispensing cells / well, but is not limited thereto.

[0038] In the present invention, the differentiation step may include, but is not limited to, the following steps:

[0039] A germ layer formation step for forming a germ layer in the above spheroid; and

[0040] Embedding step of embedding the spheroid in which the above germ layer is formed into Matrigel.

[0041] The above germ layer formation step may be performed in a neural induction medium (NIM), and the neural induction medium may include DMEM-F12 and may additionally include at least one selected from the group consisting of N2 supplement, GlutaMAX supplement, MEM-NEAA, and heparin.

[0042] The above germ layer formation step may be performed for 2 to 10 days, preferably 2 to 8 days, 2 to 6 days, 2 to 5 days, 4 to 10 days, 4 to 8 days, or 4 to 6 days, for example, it may be performed for 4 to 5 days, but is not limited thereto.

[0043] The differentiation step corresponding to the section after the embedding step may be performed in a cerebral organoid differentiation medium, and the cerebral organoid differentiation medium may include a mixture of DMEM-F12 and a conventional neurobasal medium, and the mixing ratio of the DMEM-F12 and the conventional neurobasal medium may be 1:0.5 to 1:2 (v / v), preferably 1:0.5 to 1:1.8 (v / v), 1:0.5 to 1:1.5 (v / v), 1:0.5 to 1:1.2 (v / v), 1:0.5 to 1:1 (v / v), 1:0.8 to 1:2 (v / v), 1:0.8 to 1:1.8 (v / v), 1:0.8 to 1:1.5 (v / v), 1:0.8 to It may be 1:1.2 (v / v), 1:0.8 to 1:1 (v / v), 1:1 to 1:2 (v / v), 1:1 to 1:1.8 (v / v), or 1:1 to 1:1.5 (v / v), for example, but not limited to, 1:1 to 1:1.2 (v / v).

[0044] The above cerebral organoid differentiation medium may additionally include at least one selected from the group consisting of N2 supplement, insulin, GlutaMAX supplement, MEM-NEAA, penicillin-streptomycin, 2-mercaptoethanol, and B27 supplement not containing vitamin A.

[0045] The differentiation step corresponding to the section after the embedding step may be performed for 2 to 10 days, preferably 2 to 8 days, 2 to 6 days, 2 to 5 days, 4 to 10 days, 4 to 8 days, or 4 to 6 days, and for example, may be performed for 4 to 5 days, but is not limited thereto.

[0046] In the present invention, the growth step may be performed by replacing the medium with a B27 supplement containing vitamin A.

[0047] In the present invention, the test material may be at least one selected from the group consisting of diesel exhaust particles, particulate matter (PM), and total suspended particles (TSP), and may be, for example, diesel exhaust particles, but is not limited thereto.

[0048] In the present invention, the growth step may be performed for 15 to 90 days, preferably 15 to 80 days, 15 to 70 days, 15 to 60 days, 15 to 50 days, 15 to 40 days, 15 to 30 days, 25 to 90 days, 25 to 80 days, 25 to 70 days, 25 to 60 days, 25 to 50 days, or 25 to 40 days, and for example, it may be performed for 25 to 30 days, but is not limited thereto.

[0049] In the present invention, the structural damage or functional damage may be at least one selected from the group consisting of a 20 to 70% reduction in the tissue size of the cerebral organoid, a decrease in the expression level of a brain nerve tissue expression marker (MAP2), an increase in the expression level of an inflammatory response-related factor, an imbalance in the expression of GABA-glutamate, inactivity of bioelectrical signals, and a decrease in the expression level of a neuronal synapse-related marker, but is not limited thereto.

[0050] Another aspect of the present invention is a method for screening a candidate substance for treating a brain and nerve developmental disease, comprising the following steps:

[0051] Spheroid formation step of forming spheroids by suspending and culturing stem cells;

[0052] A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A and differentiated into cerebral organoids;

[0053] A contact step in which a toxic substance or therapeutic candidate is brought into contact with the neuroepithelial bud formed in the above cerebral organoid;

[0054] A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and

[0055] An analysis step that compares the degree of improvement in structural or functional damage according to the presence or absence of contact with a therapeutic candidate substance or the amount of treatment among brain organoids exposed to a toxic substance.

[0056] In the present invention, the stem cell may be at least one selected from the group consisting of human induced pluripotent stem cells (hiPSCs), human embryonic stem cells (hESCs), and human pluripotent stem cells (hPSCs), and may be, for example, hiPSCs, but is not limited thereto.

[0057] In the present invention, the spheroid formation step may be performed by distributing stem cells separated into single cells and suspended in culture to form spheroids at 10,000 to 1,000,000 cells / well, preferably 10,000 to 500,000 cells / well, 10,000 to 200,000 cells / well, 10,000 to 100,000 cells / well, 20,000 to 1,000,000 cells / well, 20,000 to 500,000 cells / well, 20,000 to 200,000 cells / well, 20,000 to 100,000 cells / well, 50,000 to 1,000,000 cells / well, 50,000 to 500,000 It may be performed by dispensing cells / well, 50,000 to 200,000 cells / well, 50,000 to 100,000 cells / well, 100,000 to 1,000,000 cells / well, or 100,000 to 500,000 cells / well, and for example, it may be performed by dispensing cells / well, but is not limited thereto.

[0058] In the present invention, the differentiation step may include, but is not limited to, the following steps:

[0059] A germ layer formation step for forming a germ layer in the above spheroid; and

[0060] An embedding step in which the spheroid in which the above germ layer is formed is embedded in Matrigel.

[0061] The above germ layer formation step may be performed in a neural induction medium (NIM), and the neural induction medium may include DMEM-F12 and may additionally include at least one selected from the group consisting of N2 supplement, GlutaMAX supplement, MEM-NEAA, and heparin.

[0062] The above germ layer formation step may be performed for 2 to 10 days, preferably 2 to 8 days, 2 to 6 days, 2 to 5 days, 4 to 10 days, 4 to 8 days, or 4 to 6 days, for example, it may be performed for 4 to 5 days, but is not limited thereto.

[0063] The differentiation step corresponding to the section after the embedding step may be performed in a cerebral organoid differentiation medium, and the cerebral organoid differentiation medium may include a mixture of DMEM-F12 and a conventional neuronal cell culture medium, and the mixing ratio of the DMEM-F12 and the conventional neuronal cell culture medium may be 1:0.5 to 1:2 (v / v), preferably 1:0.5 to 1:1.8 (v / v), 1:0.5 to 1:1.5 (v / v), 1:0.5 to 1:1.2 (v / v), 1:0.5 to 1:1 (v / v), 1:0.8 to 1:2 (v / v), 1:0.8 to 1:1.8 (v / v), 1:0.8 to 1:1.5 (v / v), 1:0.8 to 1:1.2 (v / v), 1:0.8 It may be 1:1 (v / v), 1:1 to 1:2 (v / v), 1:1 to 1:1.8 (v / v), or 1:1 to 1:1.5 (v / v), for example, but not limited to, 1:1 to 1:1.2 (v / v).

[0064] The above cerebral organoid differentiation medium may additionally include at least one selected from the group consisting of N2 supplement, insulin, GlutaMAX supplement, MEM-NEAA, penicillin-streptomycin, 2-mercaptoethanol, and B27 supplement not containing vitamin A.

[0065] The differentiation step corresponding to the section after the embedding step may be performed for 2 to 10 days, preferably 2 to 8 days, 2 to 6 days, 2 to 5 days, 4 to 10 days, 4 to 8 days, or 4 to 6 days, and for example, may be performed for 4 to 5 days, but is not limited thereto.

[0066] In the present invention, the growth step may be performed by replacing the medium with a B27 supplement containing vitamin A.

[0067] In the present invention, the test material may be at least one selected from the group consisting of diesel exhaust particles, fine dust, and total dust, and may be, for example, diesel exhaust particles, but is not limited thereto.

[0068] In the present invention, the growth step may be performed for 15 to 90 days, preferably 15 to 80 days, 15 to 70 days, 15 to 60 days, 15 to 50 days, 15 to 40 days, 15 to 30 days, 25 to 90 days, 25 to 80 days, 25 to 70 days, 25 to 60 days, 25 to 50 days, or 25 to 40 days, and for example, it may be performed for 25 to 30 days, but is not limited thereto.

[0069] In the present invention, the structural damage or functional damage may be at least one selected from the group consisting of a 20 to 70% reduction in the tissue size of the cerebral organoid, a decrease in the expression level of a brain nerve tissue expression marker (MAP2), an increase in the expression level of an inflammatory response-related factor, an imbalance in the expression of GABA-glutamate, inactivity of bioelectrical signals, and a decrease in the expression level of a neuronal synapse-related marker, but is not limited thereto.

[0070] The present invention relates to a method for screening for a neurotoxic substance or a candidate substance for the treatment of a neurodevelopmental disease using a cerebral organoid, and by utilizing the screening system, it is possible to evaluate the effects of nanomaterials contained in air pollutants, foods encountered in daily life, and especially food formulations for improving absorption and function such as nano-calcium, as well as food additives, preservatives, and packaging materials for facilitating storage and distribution, on brain neural tissue and synaptic plasticity.

[0071] FIG. 1a is a schematic diagram showing the differentiation process from human induced pluripotent stem cells (hiPSCs) to cerebral organoids according to one embodiment of the present invention.

[0072] FIG. 1b is a photograph showing tissue changes resulting from differentiation of human induced pluripotent stem cells into cerebral organoids according to one embodiment of the present invention.

[0073] Figure 1c is a photograph showing the results of performing fluorescent immunostaining for differentiation markers TTR, TUJ1, FOXG1, and PROX1 from the tissue of a cerebral organoid after making it transparent according to one embodiment of the present invention.

[0074] FIG. 2A is a schematic diagram illustrating a process of differentiating human induced pluripotent stem cells into cerebral organoids by treating nanoparticles in a process of inducing tissue growth and differentiation according to one embodiment of the present invention.

[0075] FIG. 2b is an optical microscope and fluorescence microscope photograph showing cerebral organoids treated with nanoparticles at different concentrations during the differentiation process according to one embodiment of the present invention.

[0076] Figure 2c is a graph showing the area of ​​cerebral organoids treated with nanoparticles at different concentrations during the differentiation process according to one embodiment of the present invention.

[0077] FIG. 3 is a photograph showing the results of fluorescence immunostaining for the expression levels of inflammation-related markers c-fos and p-ERK in cerebral organoids treated with nanoparticles during the differentiation process according to one embodiment of the present invention.

[0078] FIG. 4 is a photograph showing the results of fluorescence immunostaining for the expression of excitatory-inhibitory neurotransmitters GABA-Glutamate in cerebral organoids treated with nanoparticles during the differentiation process according to one embodiment of the present invention.

[0079] FIG. 5A is a photograph showing electrophysiological signals of cerebral organoids treated with nanoparticles during a differentiation process according to one embodiment of the present invention.

[0080] FIG. 5b is a photograph showing the results of fluorescence immunostaining for the expression levels of synaptophysin and PSD95 in cerebral organoids treated with nanoparticles during the differentiation process according to one embodiment of the present invention.

[0081] The present invention relates to a method for screening for neurotoxic substances comprising the following steps:

[0082] Spheroid formation step in which stem cells are suspended and cultured to form spheroids;

[0083] A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A to differentiate them into cerebral organoids;

[0084] A contact step in which a test substance is brought into contact with the neuroepithelial bud formed in the above cerebral organoid;

[0085] A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and

[0086] An analysis step for comparing the degree of occurrence of structural or functional damage in the above cerebral organoids with that of a control group that was not exposed to the test substance.

[0087] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are intended only to illustrate the present invention, and the scope of the present invention is not limited by these examples.

[0088] Throughout this specification, "%" used to indicate the concentration of a particular substance is (wt / wt)% for solid / solid, (wt / vol)% for solid / liquid, and (vol / vol)% for liquid / liquid, unless otherwise stated.

[0089]

[0090] Example 1: Production of cerebral organoids

[0091] 1-1. Spheroid production and differentiation induction

[0092] Human induced pluripotent stem cells (hiPSCs) are stem cells that have been engineered to possess pluripotency, similar to embryonic stem cells, by introducing four specific genes (Oct4, Sox2, Klf4, and c-Myc) that induce reprogramming of differentiated adult somatic cells. IPS cells are free from ethical concerns and immune rejection, and are capable of differentiating into various tissues, making them useful for research in embryology, as well as for the treatment of various diseases and treatments.

[0093] As shown in Figures 1a and 1b, human induced pluripotent stem cells were cultured in StemFit Basic002 medium on culture vessels coated with iMatrix-511, a laminin-based protein. Once the cells reached 70–80% confluence, they were isolated into single cells using TrypLE Select. The isolated cells were resuspended after centrifugation and seeded into well plates (Ultra-low attachment 96-well plates) at a density of 100,000 cells / well to form spheroids.

[0094] When the manufactured spheroids had a diameter of approximately 500 to 600 μm, they were cultured for 4 to 5 days in neural induction medium (NIM) containing DMEM-F12, 1X N2 supplement, 1X GlutaMAX supplement, 1X MEM-NEAA, and 1 μg / ml heparin.

[0095] Spheroids with a germ layer formed were embedded in Matrigel and cultured for approximately 5 days in cerebral organoid differentiation medium containing 0.5X N2 supplement, 62.5 μl insulin, 1X GlutaMAX supplement, 0.5X MEM-NEAA, 1X penicillin-streptomycin, 10 μM 2-mercaptoethanol, and 1X B27 supplement without vitamin A in a 1:1 (v / v) mixture of DMEM-F12 and Neurobasal medium.

[0096] Once neuroepithelial buds were formed, the cerebral organoid differentiation medium was replaced with 1X B27 supplement containing vitamin A to induce differentiation for approximately 15 days, and cerebral organoids were produced.

[0097]

[0098] 1-2. Confirmation of markers related to cerebral organoids

[0099] To confirm the expression of specific markers in the produced cerebral organoids, tissue clearing and fluorescent immunostaining were performed. Cerebral organoids that had undergone differentiation and culture for more than three months were fixed in 4% paraformaldehyde. Protein expression within the tissue was observed through tissue clearing using a kit (Tissue Clearing Kit, BINAREE).

[0100] Fluorescent immunostaining was performed using FOXG1 and TTR, which are markers of cerebral organoids, TUJ1, which is a neuronal marker, and SOX2, which is a stem cell marker, and fluorescence was confirmed using a confocal microscope.

[0101] As can be seen in Figure 1c, markers expressed in neural cells were observed instead of characteristics exhibited in stem cells in the produced cerebral organoids.

[0102]

[0103] Example 2: Cellular and Tissue Changes in Cerebral Organoids Following Treatment with Nano-Sized Diesel Exhaust Particles

[0104] 2-1. Method for treating nano-sized diesel exhaust particles

[0105] Changes in cells and tissues were observed through tissue clearing and fluorescent immunostaining processes in cerebral organoids exposed to nanoparticle solutions corresponding to diesel exhaust particles.

[0106] To perform the brain organoid preparation process as in Fig. 2a, purchased nano-scale diesel exhaust particles (Nano scale Diesel particulate matter, SRM 2975, NIST) were diluted in DPBS (Dulbecco's phosphate-buffered saline) at a concentration of 1 mg / ml and sonicated at 4°C for 30 minutes to prepare a nanoparticle solution stock.

[0107] The above nanoparticle solutions were applied to cerebral organoids at the growth stage, where tissue differentiation and growth are induced after germinal layer formation, at concentrations of 1, 5, and 10 μg / ml, respectively. After 8 hours, the medium containing the nanoparticles was removed, washed with DPBS, and replaced with culture medium. This process was repeated at 3-day intervals for 30 days, and then observed using optical and fluorescence microscopy.

[0108] As can be seen in Figures 2b and 2c, as the concentration of the nanoparticle solution increased, the size of the tissue became smaller compared to the normal cerebral tissue (Control), and thus, it was expected that growth would slow down. When the concentration of the nanoparticle solution was 10 ug / ml, some tissues were damaged and the size of the tissue decreased rapidly. In addition, it was confirmed that the expression level of MAP2, a marker expressed in mature brain tissue, decreased as the concentration of the nanoparticle solution increased, confirming that the maturation of neural cells was inhibited by nanoparticles.

[0109] Subsequent comparative experiments were conducted by treating normal cerebral organoids and cerebral organoids with nanoparticles at a concentration of 5 μg / ml, which can exclude damage to external tissues.

[0110]

[0111] 2-2. Confirmation of inflammatory response following nanoparticle treatment

[0112] To determine whether nanoparticle treatment increased the inflammatory response, c-fos and p-ERK, representative nervous system immune response substances, were identified through fluorescent immunostaining. As in Example 2-1, normal cerebral organoids and cerebral organoids exposed to 5 ug / ml concentrations of nanoparticles were observed using a confocal microscope after tissue clearing and fluorescent immunostaining.

[0113] As can be seen in Figure 3, the expression of c-fos and p-ERK increased in cerebral organoids exposed to the nanoparticle solution, indicating that the nanoparticles induce an inflammatory response in the brain neural tissue.

[0114]

[0115] 2-3. Confirmation of neurotransmitter secretion imbalance following nanoparticle treatment

[0116] To determine whether there was an imbalance in neurotransmitter secretion following nanoparticle treatment, we examined changes in the expression patterns of GABA and glutamate, representative excitatory-inhibitory neurotransmitters. As in Example 2-1, normal cerebral organoids and cerebral organoids exposed to 5 ug / ml nanoparticles were observed using a confocal microscope after tissue transparency and fluorescent immunostaining.

[0117] As can be seen in Figure 4, in the case of cerebral organoids exposed to nanoparticles, there was no significant change in the expression of GABA (GAD67), but the expression of glutamate (vGlut1) increased, indicating an imbalance between the two neurotransmitters.

[0118]

[0119] 2-4. Measurement of bioelectrical signal changes following nanoparticle treatment

[0120] Changes in bioelectrical signals of cerebral organoids repeatedly exposed to nanoparticles at a concentration of 5 μg / ml were observed.

[0121] Specifically, electrical signals were confirmed for cerebral organoids that had undergone differentiation and culture using a multielectrode array system (MEA). The MEA substrate was coated with polyetherimide (PEI) and then re-coated with laminin. The cerebral organoids that had undergone differentiation and maturation and the cerebral organoids exposed to fine dust were placed on it, and bioelectrical signals were measured using the Maestro MEA system (Axion Biosystems). Afterwards, firing signals were observed simultaneously from multiple electrodes to confirm neural network formation and whether the neural network was damaged by nanoparticles.

[0122] As shown in Figure 5a, normal cerebral organoids not treated with nanoparticles were able to detect biosignals simultaneously from multiple electrodes, suggesting that neural network connectivity was normal. In contrast, cerebral organoids treated with nanoparticles detected signals from multiple electrodes but did not activate simultaneously, suggesting that neural network formation was abnormal.

[0123]

[0124] 2-5. Observation of changes in synapse formation following nanoparticle treatment

[0125] To infer whether the neural network within cerebral organoid tissue is damaged by nanoparticle treatment based on changes in synapse formation, the expression of synaptophysin and PSD95 was confirmed through fluorescent immunostaining. As in Example 1-2, normal cerebral organoids and cerebral organoids exposed to nanoparticles were observed using a confocal microscope after tissue transparency and fluorescent immunostaining, respectively.

[0126] As shown in Figure 5b, normal cerebral organoids showed evenly distributed expression of synaptophysin and PSD95, whereas nanoparticle-exposed cerebral organoids showed only localized expression. This result, similar to the electrophysiological signals observed through MEA, suggests that nanoparticle exposure can impair synapse formation in neurons.

[0127] The present invention relates to a method for screening a neurotoxic substance or a candidate substance for treating a neurodevelopmental disease using a cerebral organoid, and more specifically, to providing a cerebral organoid that can be used as a model for screening because the growth is affected when a toxic substance is treated during the process of inducing growth and differentiation of a cerebral organoid tissue, and can also be used as an evaluation index for a neurodevelopmental disease of the neurodevelopmental system of the brain.

Claims

1. A method for screening neurotoxic substances comprising the following steps: Spheroid formation step in which stem cells are suspended and cultured to form spheroids; A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A to differentiate them into cerebral organoids; A contact step in which a test substance is brought into contact with the neuroepithelial bud formed in the above cerebral organoid; A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and An analysis step for comparing the degree of occurrence of structural or functional damage in the above cerebral organoids with that of a control group that was not exposed to the test substance.

2. A method for screening for a neurotoxic substance in claim 1, wherein the stem cells are at least one selected from the group consisting of human induced pluripotent stem cells (hiPSCs), human embryonic stem cells (hESCs), and human pluripotent stem cells (hPSCs).

3. A method for screening for neurotoxic substances in accordance with claim 1, wherein the differentiation step comprises the following steps: A germ layer formation step for forming a germ layer in the above spheroid; and Embedding step of embedding the spheroid in which the above germ layer is formed into Matrigel.

4. A method for screening for neurotoxic substances in paragraph 1, wherein the test substance is at least one selected from the group consisting of diesel exhaust particulate matter (DPM), particulate matter (PM), and total suspended particles (TSP).

5. A method for screening for neurotoxic substances in the first paragraph, wherein the growth step is performed for 15 to 60 days.

6. A method for screening for a neurotoxic substance in paragraph 1, wherein the structural damage or functional damage is at least one selected from the group consisting of a 20 to 70% decrease in the tissue size of a cerebral organoid, a decrease in the expression level of a brain nerve tissue expression marker (MAP2), an increase in the expression level of an inflammatory response-related factor, an imbalance in the expression of GABA-glutamate, inactivity of bioelectrical signals, and a decrease in the expression level of a neuronal synapse-related marker.

7. A method for screening candidate substances for the treatment of neurodevelopmental disorders, including the following steps: Spheroid formation step in which stem cells are suspended and cultured to form spheroids; A differentiation step in which the above spheroids are cultured in a medium that does not contain vitamin A to differentiate them into cerebral organoids; A contact step in which a toxic substance or therapeutic candidate is brought into contact with the neuroepithelial bud formed in the above cerebral organoid; A growth step in which the above cerebral organoids are cultured and grown in a medium containing vitamin A; and An analysis step that compares the degree of improvement in structural or functional damage according to the presence or absence of contact with a therapeutic candidate substance or the amount of treatment among brain organoids exposed to a toxic substance.

8. A method for screening a candidate substance for treating a brain and nerve developmental disease, wherein the stem cell is at least one selected from the group consisting of human induced pluripotent stem cells (hiPSCs), human embryonic stem cells (hESCs), and human pluripotent stem cells (hPSCs).

9. In the 7th paragraph, the differentiation step comprises the following steps: a method for screening a candidate substance for treating a brain and nerve developmental disease: A germ layer formation step for forming a germ layer in the above spheroid; and Embedding step of embedding the spheroid in which the above germ layer is formed into Matrigel.

10. A method for screening a candidate substance for treating a brain and nerve developmental disease, wherein the toxic substance is at least one selected from the group consisting of diesel exhaust particulate matter (DPM), particulate matter (PM), and total suspended particles (TSP).

11. A method for screening a candidate substance for treating a brain and nerve developmental disease, wherein the growth stage is performed for 15 to 60 days in the 7th paragraph.

12. A method for screening a candidate substance for treating a brain nerve developmental disease, wherein the structural damage or functional damage is at least one selected from the group consisting of a 20 to 70% decrease in the tissue size of a cerebral organoid, a decrease in the expression level of a brain nerve tissue expression marker (MAP2), an increase in the expression level of an inflammatory response-related factor, an imbalance in the expression of GABA-glutamate, inactivity of bioelectrical signals, and a decrease in the expression level of a neuronal synapse-related marker.

Citation Information

Patent Citations

  • Water-cooled, fast-charging cables using heat pipes

    KR1020220003724A

  • Chicken automatic frying system

    KR102341587B1

Cited By

  • PFOS corticobrain organ injury model and construction method and application thereof

    CN119464212A